Knopp Biosciences, University of Leicester release details of phase 2 trial of dexpramipexole in severe eosinophilic asthma
The 52-week, randomized, double-blind, placebo-controlled trial will evaluate whether dexpramipexole is associated with a reduction in asthma exacerbations. Fifteen severe asthma centers across the United Kingdom (UK) will